Personalizing Perioperative Chemotherapy in Colon Cancer

Abstract

The traditional, surgery-first approach for colon cancer is increasingly challenged by our evolving understanding of tumor biology and a growing number of measurable tumor features that can help guide contemporary treatment plans. Certain tumor characteristics now make it practical to challenge locally advanced colon cancer with neoadjuvant chemotherapy or immunotherapy, and allow for targeted postoperative therapies. The contemporary data supporting these tailored approaches to integrating systemic therapy before or after resection are summarized in this article.

Keywords

colon cancer - chemotherapy - microsatellite instability - next-generation sequencing

Publication History

Article published online:
15 January 2025

• References

• 1 Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 2020; 20 (01) 16
• 2 Alonso S, Saltz L. The landmark series: chemotherapy for non-metastatic colon cancer. Ann Surg Oncol 2021; 28 (02) 995-1001
• 3 André T, Boni C, Mounedji-Boudiaf L. et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23) 2343-2351
• 4 Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13 (11) 1152-1160
• 5 Morton D, Seymour M, Magill L. et al; FOxTROT Collaborative Group. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol 2023; 41 (08) 1541-1552
• 6 Taieb J, Karoui M. FOxTROT: are we ready to dance?. J Clin Oncol 2023; 41 (08) 1514-1517
• 7 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed September 30, 2024 at: https://www.nccn.org/
• 8 Sargent DJ, Marsoni S, Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28 (20) 3219-3226
• 9 Chalabi M, Fanchi LF, Dijkstra KK. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26 (04) 566-576
• 10 Chalabi M, Verschoor YL, Tan PB. et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med 2024; 390 (21) 1949-1958
• 11 de Gooyer PGM, Verschoor YL, van den Dungen LDW. et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med 2024; 30 (11) 3284-3290
• 12 Boland PM, Ma WW. Immunotherapy for colorectal cancer. Cancers (Basel) 2017; 9 (05) 50
• 13 Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
• 14 Overman MJ, McDermott R, Leach JL. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18 (09) 1182-1191
• 15 André T, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383 (23) 2207-2218
• 16 Grothey A, Sobrero AF, Shields AF. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018; 378 (13) 1177-1188
• 17 Bennouna J, André T, Campion L. et al. Rationale and design of the IROCAS study: multicenter, international, randomized phase 3 trial comparing adjuvant modified (m) FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer—a UNICANCER GI-PRODIGE trial. Clin Colorectal Cancer 2019; 18 (01) e69-e73
• 18 Lee KH, Yang IJ, Ha GW. et al. mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial. BMC Cancer 2024; 24 (01) 397
• 19 Van Cutsem E, Labianca R, Bodoky G. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27 (19) 3117-3125
• 20 Gruenberger T, Bridgewater J, Chau I. et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015; 26 (04) 702-708
• 21 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
• 22 Krell M, Llera B, Brown ZJ. Circulating tumor DNA and management of colorectal cancer. Cancers (Basel) 2023; 16 (01) 21
• 23 Reinert T, Schøler LV, Thomsen R. et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2016; 65 (04) 625-634
• 24 Tie J, Cohen JD, Lahouel K. et al; DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022; 386 (24) 2261-2272
• 25 Cremolini C, Rossini D, Dell'Aquila E. et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 2019; 5 (03) 343-350
• 26 Bando H, Nakamura Y, Taniguchi H. et al. Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis Oncol 2022; 6 (06) e2100535